The Insider Jacques Gonella Unloaded 200000 shares of Antares Pharma, Inc. (ATRS); Tronox Limited Ordinary Shares Class A $0.01 Par (TROX) SI Decreased By 20.63%

May 16, 2018 - By Kurt Siggers

Tronox Limited (NYSE:TROX) Logo

Tronox Limited Ordinary Shares Class A $0.01 Par (NYSE:TROX) had a decrease of 20.63% in short interest. TROX’s SI was 1.96 million shares in May as released by FINRA. Its down 20.63% from 2.47 million shares previously. With 1.08 million avg volume, 2 days are for Tronox Limited Ordinary Shares Class A $0.01 Par (NYSE:TROX)’s short sellers to cover TROX’s short positions. The SI to Tronox Limited Ordinary Shares Class A $0.01 Par’s float is 2.19%. The stock increased 1.43% or $0.25 during the last trading session, reaching $17.68. About 481,056 shares traded. Tronox Limited (NYSE:TROX) has risen 9.88% since May 16, 2017 and is uptrending. It has underperformed by 1.67% the S&P500.

More news for Tronox Limited (NYSE:TROX) were recently published by: Seekingalpha.com, which released: “Tronox’s (TROX) CEO Jeff Quinn on Q1 2018 Results – Earnings Call Transcript” on May 14, 2018. Streetinsider.com‘s article titled: “Tronox (TROX) Reports Option Agreement to Purchase Majority of Advanced Metal Industries Co. Jazan Slagger …” and published on May 10, 2018 is yet another important article.

Tronox Limited produces and markets titanium bearing mineral sands and titanium dioxide pigment in North America, Europe, South Africa, and the Asia-Pacific region. The company has market cap of $2.17 billion. It primarily operates in two divisions, TiO2 and Alkali. It currently has negative earnings. The TiO2 segment engages in the exploration, mining, and beneficiation of mineral sands deposits.

Among 10 analysts covering Tronox (NYSE:TROX), 8 have Buy rating, 1 Sell and 1 Hold. Therefore 80% are positive. Tronox had 23 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Alembic with “Buy” on Monday, October 23. The stock of Tronox Limited (NYSE:TROX) earned “Buy” rating by Barclays Capital on Thursday, December 14. The stock of Tronox Limited (NYSE:TROX) has “Buy” rating given on Monday, June 26 by Alembic. Alembic maintained the shares of TROX in report on Thursday, March 1 with “Buy” rating. Barclays Capital maintained it with “Overweight” rating and $26 target in Monday, March 12 report. UBS maintained it with “Sell” rating and $18 target in Thursday, November 9 report. The firm has “Sell” rating given on Friday, October 13 by UBS. The firm has “Buy” rating given on Tuesday, March 27 by BMO Capital Markets. The stock of Tronox Limited (NYSE:TROX) has “Outperform” rating given on Thursday, August 13 by RBC Capital Markets. The rating was initiated by Wells Fargo with “Buy” on Wednesday, February 7.

Investors sentiment increased to 2.06 in 2017 Q4. Its up 0.92, from 1.14 in 2017Q3. It improved, as 19 investors sold Tronox Limited shares while 35 reduced holdings. 47 funds opened positions while 64 raised stakes. 81.33 million shares or 29.62% more from 62.74 million shares in 2017Q3 were reported. Century has invested 0% in Tronox Limited (NYSE:TROX). Royal National Bank Of Canada stated it has 305 shares. Susquehanna Gru Limited Liability Partnership has invested 0% in Tronox Limited (NYSE:TROX). Los Angeles Capital Mngmt & Equity reported 36,526 shares stake. The Minnesota-based Gradient Investments Ltd has invested 0% in Tronox Limited (NYSE:TROX). Retail Bank Of Montreal Can accumulated 417 shares or 0% of the stock. Pnc Serv Gp holds 0% or 70 shares. Jpmorgan Chase Comm reported 0% in Tronox Limited (NYSE:TROX). The Maryland-based Proshare Advisors Ltd Liability Corp has invested 0% in Tronox Limited (NYSE:TROX). Tide Point Capital Management L P invested 2.36% of its portfolio in Tronox Limited (NYSE:TROX). Private Cap Mngmt Ltd Liability Corporation holds 4.55% of its portfolio in Tronox Limited (NYSE:TROX) for 1.38M shares. Tiaa Cref Inv Management Limited Liability Company reported 0.11% stake. Jane Street Ltd Llc has 0% invested in Tronox Limited (NYSE:TROX) for 25,022 shares. Macquarie Gru Ltd has invested 0% in Tronox Limited (NYSE:TROX). Moreover, Virginia Retirement Et Al has 0.01% invested in Tronox Limited (NYSE:TROX) for 37,800 shares.

Investors sentiment decreased to 1.16 in Q4 2017. Its down 0.13, from 1.29 in 2017Q3. It dropped, as 9 investors sold Antares Pharma, Inc. shares while 29 reduced holdings. 19 funds opened positions while 25 raised stakes. 54.49 million shares or 1.74% more from 53.56 million shares in 2017Q3 were reported. 41,433 are held by Credit Suisse Ag. Zeke Advsrs Limited Liability Company holds 0% or 10,811 shares in its portfolio. Ballentine Prtnrs Ltd Liability Company, Massachusetts-based fund reported 100,000 shares. Group One Trading Ltd Partnership reported 15,257 shares stake. International Group holds 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS) for 96,793 shares. Creative Planning holds 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS) for 13,500 shares. Jpmorgan Chase reported 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). Goldman Sachs Group Inc Inc, New York-based fund reported 129,470 shares. New York State Common Retirement Fund accumulated 141,800 shares. Armistice Capital Ltd holds 7.60M shares. Invesco Limited reported 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Sii Investments Wi has 15,800 shares for 0% of their portfolio. California Pub Employees Retirement has 805,200 shares. Proshare Llc invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Panagora Asset has 906,017 shares for 0.01% of their portfolio.

Among 4 analysts covering Antares Pharma (NASDAQ:ATRS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Antares Pharma has $600 highest and $3.0 lowest target. $4.50’s average target is 75.10% above currents $2.57 stock price. Antares Pharma had 14 analyst reports since March 9, 2016 according to SRatingsIntel. H.C. Wainwright maintained Antares Pharma, Inc. (NASDAQ:ATRS) rating on Wednesday, March 14. H.C. Wainwright has “Buy” rating and $3.5 target. H.C. Wainwright maintained Antares Pharma, Inc. (NASDAQ:ATRS) on Thursday, February 15 with “Buy” rating. As per Monday, August 7, the company rating was maintained by Jefferies. On Tuesday, July 25 the stock rating was maintained by Piper Jaffray with “Buy”. As per Friday, June 23, the company rating was initiated by H.C. Wainwright. The rating was maintained by Jefferies with “Buy” on Wednesday, March 9. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, March 27. As per Friday, September 8, the company rating was initiated by H.C. Wainwright. The company was maintained on Monday, October 23 by H.C. Wainwright. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, November 8 report.

Since May 9, 2018, it had 0 insider buys, and 1 sale for $740,400 activity. The insider GONELLA JACQUES sold 300,000 shares worth $740,400.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company has market cap of $403.04 million. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis and psoriasis patients to self-inject methotrexate at home; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It currently has negative earnings. In addition, the firm is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes and osteoporosis; Makena QuickShot auto injectors for reducing risk of preterm birth; and VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency.

Analysts await Antares Pharma, Inc. (NASDAQ:ATRS) to report earnings on August, 14. They expect $-0.02 earnings per share, 0.00% or $0.00 from last year’s $-0.02 per share. After $-0.04 actual earnings per share reported by Antares Pharma, Inc. for the previous quarter, Wall Street now forecasts -50.00% EPS growth.

The stock increased 3.21% or $0.08 during the last trading session, reaching $2.57. About 1.04 million shares traded. Antares Pharma, Inc. (NASDAQ:ATRS) has declined 23.10% since May 16, 2017 and is downtrending. It has underperformed by 34.65% the S&P500.

Jacques Gonella, the director of Antares Pharma Inc made unloading of 200,000 shares with an average price-per-share of $2.4 in the corporation, that are with a total value of $483,000 US Dollars. He also unloaded 300,000 shares worth total $740,400 USD in the last 30 days. Right now, Jacques Gonella possess a total of 11.59 million shares or 7.39% of Antares Pharma Inc’s total market cap.

Antares Pharma, Inc. (NASDAQ:ATRS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts